Home > Boards > US Listed > Biotechs > Regeneron Pharmaceuticals (REGN)

Regeneron (REGN), a large-cap biotech stock, is part

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 401
Posts 53,330
Boards Moderated 23
Alias Born 12/16/01
160x600 placeholder
Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 20... PR Newswire (US) - 10/10/2019 9:30:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 10/8/2019 2:00:39 PM
Regeneron, Sanofi Get Positive CHMP Opinion for Dupixent Dow Jones News - 9/20/2019 7:22:00 AM
The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with... PR Newswire (US) - 9/20/2019 6:59:00 AM
CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis PR Newswire (US) - 9/20/2019 6:44:00 AM
Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Der... PR Newswire (US) - 9/18/2019 6:59:00 AM
Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies PR Newswire (US) - 9/17/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/12/2019 5:01:24 PM
U.S. Federal Judge Rules for Sanofi, Regeneron in Long-Running Patent Dispute; Amgen to Appeal Dow Jones News - 8/28/2019 6:34:00 PM
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9 PR Newswire (US) - 8/28/2019 4:56:00 PM
Regeneron Announces Upcoming Investor Conference Presentation PR Newswire (US) - 8/15/2019 9:30:00 AM
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High... PR Newswire (US) - 8/14/2019 7:00:00 AM
FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe PR Newswire (US) - 8/13/2019 7:00:00 AM
Two Experimental Ebola Drugs Reduce Mortality Rate Dow Jones News - 8/12/2019 3:16:00 PM
PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths PR Newswire (US) - 8/12/2019 10:01:00 AM
Regeneron, Sanofi: Dupixent Meets Main Endpoints in Children With Severe Atopic Dermatitis Dow Jones News - 8/6/2019 9:57:00 AM
Regeneron, Sanofi Get EC OK for Dupixent in Adolescents with Atopic Dermatitis Dow Jones News - 8/6/2019 9:22:00 AM
Regeneron Lowers Capital Expenditure Guidance, Changes Other Outlook Measures Dow Jones News - 8/6/2019 8:13:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 7:56:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2019 7:36:18 AM
Regeneron's Profit Falls as Expenses Spike Dow Jones News - 8/6/2019 7:27:00 AM
Regeneron Reports Second Quarter 2019 Financial and Operating Results PR Newswire (US) - 8/6/2019 6:30:00 AM
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Der... PR Newswire (US) - 8/6/2019 1:04:00 AM
Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis PR Newswire (US) - 8/6/2019 12:59:00 AM
Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation PR Newswire (US) - 7/18/2019 7:30:00 AM
TREND1 Member Level  Monday, 09/24/18 07:19:50 PM
Re: None
Post # of 135 
Regeneron (REGN), a large-cap biotech stock, is part of the Health Care SPDR (XLV) and a top ten holding in the Biotech iShares (IBB), Both ETFs hit 52-week highs recently and show upside leadership. The stock is lagging in the 52-week high category, but the long-term trend is up and the stock is breaking out of a flag formation.
First, the long-term trend is up because the stock broke the March highs with a 39% advance from May to August. Second, the 50-day EMA is above the 200-day EMA and price is above both EMAs.
After breaking the red resistance zone in early July, the stock established support in the 360 area over the last few months. Even after a gap down in early August, the stock held this support zone and moved above the early August high. The stock has since corrected with a falling flag of sorts and is edging above the trend line as I write (Monday morning, September 24th).


The indicator windows show upside volume increasing over the last few months and the PPO turning up. Note the advance began in mid May with a surge in upside volume and upside volume has largely outpaced downside volume the last four months. The PPO (5,30,5) flattened out just above the zero line and remains just below its signal line. A bullish signal line crossover would confirm the upturn on the price chart.

All my posts are just my opinions. I receive no compensation for
posts. These posts are for entertainment purposes only. I maybe
long or short or hold no position.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist